The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer ...

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands ...